Gregory Williams's most recent trade in Eloxx Pharmaceuticals Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on Feb. 25, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 50,000 | 59,989 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 50,000 | 150,000 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.95 per share. | 25 Feb 2021 | 15,360 | 44,629 (0%) | 0% | 4.0 | 60,672 | Common Stock |
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 300,000 | 300,000 | - | - | Stock Options | |
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2021 | 1,875 | 15,000 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2021 | 1,875 | 10,632 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.44 per share. | 30 Jan 2021 | 643 | 9,989 (0%) | 0% | 3.4 | 2,212 | Common Stock |
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 1,875 | 16,875 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 1,875 | 9,382 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Gregory Williams | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.53 per share. | 30 Oct 2020 | 625 | 8,757 (0%) | 0% | 2.5 | 1,581 | Common Stock |